On June 26, 2025, the FDA removed REMS for Legend Biotech’s CAR T-cell therapies, improving patient monitoring guidelines. As of June 30, 2025, over 6,500 patients have been treated with CARVYKTI®.
AI Assistant
LEGEND BIOTECH CORP
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.